CytoDyn (CYDY) Total Non-Current Liabilities (2014 - 2026)

CytoDyn (CYDY) has 13 years of Total Non-Current Liabilities data on file, last reported at $79.2 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 12.2% year-over-year to $79.2 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $79.2 million (up 12.2% YoY) and the FY2025 annual result came in at $70.5 million, down 16.37% from the prior year.
• Total Non-Current Liabilities eased to $79.2 million in Q1 2026, from $85.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $126.2 million in Q1 2024 to a low of $69.4 million in Q3 2025.
• A 5-year average of $93.7 million and a median of $84.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 22288.22% — and 2024, when it sank 44.24%.
• Tracing CYDY's Total Non-Current Liabilities over 5 years: stood at $123.6 million in 2022, then grew by 0.0% to $123.6 million in 2023, then slumped by 42.8% to $70.7 million in 2024, then advanced by 20.39% to $85.1 million in 2025, then slipped by 6.93% to $79.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $79.2 million (Q1 2026), $85.1 million (Q4 2025), and $69.4 million (Q3 2025), per Business Quant data.